Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma

Journal of Neuro-Oncology

Volumn 101, Issue 3, 2011, Pages 457-462

  Ducray, François ^a,b   Sierra Del Rio, Monica ^a   Carpentier, Catherine ^b   Psimaras, Dimitri ^a   Idbaih, Ahmed ^a,b   Dehais, Caroline ^a   Kaloshi, Gentian ^a   Mokhtari, Karima ^a,b   Taillibert, Sophie ^a   Laigle Donadey, Florence ^a   Omuro, Antonio ^a   Sanson, Marc ^a,b   Delattre, Jean Yves ^a,b   Hoang Xuan, Khê ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

Chemotherapy; Elderly; Oligoastrocytoma; Oligodendroglioma; Radiotherapy; Temozolomide

Indexed keywords

CARMUSTINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

AGED; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DNA METHYLATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 79952189766     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0264-z     Document Type: Article

References (27)

1. Werner MH, Phuphanich S, Lyman GH (1995) The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 76:1634-1642
2. Fleury A, Menegoz F, Grosclaude P et al (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195-1202 (Pubitemid 27118217)
3. Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527-1535 (Pubitemid 46588417)
4. Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583-1588 (Pubitemid 41079795)
5. Combs SE, Wagner J, Bischof M et al (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987-992 (Pubitemid 351296114)
6. Brandes AA, Monfardini S (2003) The treatment of elderly patients with high-grade gliomas. Semin Oncol 30:58-62 (Pubitemid 38199167)
7. Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208-2214 (Pubitemid 38580342)
8. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262-2266 (Pubitemid 36444070)
9. Laigle-Donadey F, Figarella-Branger D, Chinot O et al (2010) Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol. doi:10.1007/s11060-009-0110-3
10. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323-331 (Pubitemid 36126198)
11. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC (2006) Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 24:1246-1252 (Pubitemid 46622027)
12. Ducray F, El Hallani S, Idbaih A (2009) Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 21:537-542
13. Brandes AA, Tosoni A, Cavallo G (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to emozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746-4753 (Pubitemid 46630938)
14. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714 (Pubitemid 46630566)
15. Abrey LE, Louis DN, Paleologos N et al (2007) Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314-318 (Pubitemid 47169664)
16. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722 (Pubitemid 46630567)
17. Wick W, Hartmann C, Engel C, Stoffels M et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880
18. Dehais C, Laigle-Donadey F, Marie Y et al (2006) Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107:1891-1897 (Pubitemid 44582960)
19. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
20. Chahlavi A, Kanner A, Peereboom D et al (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267-273 (Pubitemid 36342306)
21. Glass J, Hochberg FH, Gruber ML et al (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76:741-745
22. Paleologos NA, Macdonald DR, Vick NA et al (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141-1143
23. Taliansky-Aronov A, Bokstein F, Lavon I et al (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79:153-157 (Pubitemid 44349943)
24. Grant R, Liang BC, Page MA et al (1995) Age influences chemotherapy response in astrocytomas. Neurology 45:929-933
25. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479 (Pubitemid 28482012)
26. Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063-1071 (Pubitemid 36173159)
27. van den Bent MJ, Dubbink HJ, Sanson M et al (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881-5886